MedTrace Logo

Liraglutide as Additional Treatment to Insulin in Patients With Autoimmune Diabetes Mellitus

NCT03011008 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2020-03-18

No results posted yet for this study

Summary

The purpose of this study is to investigate the therapeutic effect of Liraglutide on autoimmune diabetes.

Conditions

  • Type 1 Diabetes Mellitus
  • Autoimmune Diabetes

Interventions

DRUG

Liraglutide

Dose escalation of liraglutide starts from 0.6 mg up to 1.2 mg per day.

DRUG

Insulin

Receive insulin following clinician's instruction.

Sponsors & Collaborators

  • Second Xiangya Hospital of Central South University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2020-12-31
Completion
2021-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03011008 on ClinicalTrials.gov